Top Markets
Coin of the day
Handa Pharmaceuticals, Inc. Handa Pharmaceuticals, Inc.

Handa Pharmaceuticals, Inc.

6620
Rang in aandelen #13387
Handa Pharmaceuticals, Inc. operates as a specialized drug company,... Handa Pharmaceuticals, Inc. operates as a specialized drug company, concentrating its efforts on creating and advancing new medications for diverse health issues across both the United States and China. The firm currently offers Quetiapine XR, a treatment for Schizophrenia, as well as Dexlansoprazole DR capsules. Beyond its existing portfolio, Handa is actively cultivating a robust pipeline of therapies. This includes their cutting-edge ONCORE drug delivery platform, engineered to boost patient adherence and improve the safety of tyrosine kinase inhibitor oncology drugs. Other significant projects encompass a 505(b)(2)NDA therapeutic agent, Tascenso ODT for managing multiple sclerosis, and the oncology candidates HND-033 and HND-027. Furthermore, the company's development initiatives feature HND-004, designed for diabetic patients; HND-032, intended to aid in smoking cessation; and HND-026, a gastrointestinal medication. Founded in 2014, Handa Pharmaceuticals, Inc. has its main corporate headquarters situated in Tainan City, Taiwan.
Aandeelprijs
$2.95
Marktkapitalisatie
$491.95M
Verandering (1 dag)
9.94%
Verandering (1 jaar)
8.06%
Land
TW
Handel Handa Pharmaceuticals, Inc. (6620)

Categorie

Aandelsplitsingen voor Handa Pharmaceuticals, Inc. (6620)
Het aandeel Handa Pharmaceuticals, Inc. (symbool: 6620) heeft in totaal 0 splitsingen ondergaan.
De meest recente splitsing vond plaats op Aug 31, 2026.
Eén aandeel 6620 dat vóór Aug 31, 2026 werd gekocht, staat nu gelijk aan 0 aandelen 6620.
Lijst van aandelen splitsingen
Jaar Splitsing Vermenigvuldiging Cumulatieve vermenigvuldiging
Niet genoeg gegevens voor de verstrekte datums.
Aandelsplitsingen van vergelijkbare bedrijven of concurrenten